A61P 25/28, A61K 31/352, A61K 31/4045
Alzheimer's disease is treated using THC (alone, or in combination with melatonin) administered in an ultra-low dose amount sufficient to (i) reduce AÎ² protein levels; (ii) reduce AÎ² aggregation: (iii) maintain AÎ²PP protein levels; (iv) enhance mitochondrial functioning; (v) decrease phosphorylation of GSK-3Î² protein; (vi) decrease GSK-3Î² protein levels; (vii) decrease phosphorylation of Tau protein; and/or (viii) maintain Tau protein levels, in said patient without severe psychological impairments and side effects associated with higher doses of THC.
Cao, Chuanhai, "Extreme low dose THC as a therapeutic and prophylactic agent for Alzheimer's disease" (2022). USF Patents. 1304.
University of South Florida